# ARMS - Rapidly Generated Multivirus-Specific CTLs for Prophylaxis & Treatment of EBV, CMV, Adenovirus, HHV6 & BK Virus

> **NCT01570283** · PHASE1,PHASE2 · COMPLETED · sponsor: **AlloVir** · enrollment: 21 (actual)

## Conditions studied

- Viral Infection

## Interventions

- **BIOLOGICAL:** Multivirus-specific T cells Dose Level 1
- **BIOLOGICAL:** Multivirus-specific T cells Dose Level 2
- **BIOLOGICAL:** Multivirus-specific T cells Dose Level 3

## Key facts

- **NCT ID:** NCT01570283
- **Lead sponsor:** AlloVir
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-09
- **Primary completion:** 2016-08
- **Final completion:** 2017-09
- **Target enrollment:** 21 (ACTUAL)
- **Last updated:** 2019-05-30

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01570283

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01570283, "ARMS - Rapidly Generated Multivirus-Specific CTLs for Prophylaxis & Treatment of EBV, CMV, Adenovirus, HHV6 & BK Virus". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01570283. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*